v3.22.2.2
Revenue Recognition (Tables)
 9 Months Ended
Oct. 01, 2022
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
We generated net sales in the following geographic locations(1) (in millions):
Three Months EndedNine Months Ended
October 1, 2022October 2, 2021October 1, 2022October 2, 2021
U.S.$716.1 $657.4 $2,116.7 $1,859.0 
Europe(2)
365.1 334.5 1,098.8 1,037.6 
All other countries(3)
19.0 50.8 80.8 137.2 
Total net sales$1,100.2 $1,042.7 $3,296.3 $3,033.8 

(1) The net sales by geographic locations is derived from the location of the entity that sells to a third party.
(2) Includes Ireland net sales of $6.2 million and $20.1 million for the three and nine months ended October 1, 2022, respectively, and $7.6 million and $17.4 million for the three and nine months ended October 2, 2021, respectively.
(3) Includes net sales generated primarily in Mexico, Australia and Canada.
The following is a summary of our net sales by category (in millions):
Three Months EndedNine Months Ended
October 1, 2022October 2, 2021October 1, 2022October 2, 2021
CSCA(1)
Upper Respiratory$132.2 $121.9 $430.9 $345.8 
Nutrition124.4 105.3 376.7 293.3 
Digestive Health119.6 110.6 363.3 344.0 
Pain and Sleep-Aids104.0 108.4 309.5 292.9 
Oral Care83.6 76.7 230.6 227.4 
Healthy Lifestyle73.8 72.1 208.7 213.0 
Skin Care48.9 46.4 138.4 139.1 
Women's Health12.4 10.4 32.6 28.7 
Vitamins, Minerals, and Supplements ("VMS")7.1 8.1 23.0 24.3 
Other CSCA(2)
16.3 34.3 46.5 48.5 
Total CSCA722.3 694.2 2,160.2 1,957.0 
CSCI
Skin Care132.4 114.2 342.1 304.3 
Upper Respiratory63.2 52.3 184.6 137.4 
VMS45.9 54.6 146.1 171.2 
Pain and Sleep-Aids29.0 33.7 130.8 131.4 
Healthy Lifestyle25.0 37.1 105.4 134.5 
Women's Health29.9 13.4 67.3 42.1 
Oral Care20.2 23.1 65.1 70.6 
Digestive Health4.1 5.7 13.3 15.5 
Other CSCI(3)
28.2 14.4 81.4 69.8 
Total CSCI377.9 348.5 1,136.1 1,076.8 
Total net sales$1,100.2 $1,042.7 $3,296.3 $3,033.8 
(1) Includes net sales from our OTC contract manufacturing business.
(2) Consists primarily of product sales and royalty income related to supply and distribution agreements, diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.
(3) Consists primarily of liquid licensed products, our distribution business, rare disease products, and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.
Contract with Customer Balances
The following table provides information about contract assets from contracts with customers (in millions):
Balance Sheet LocationOctober 1, 2022December 31, 2021
Short-term contract assetsPrepaid expenses and other current assets$31.8 $40.2